title: Outcome of crizotinib treatment in a young woman with heavily pretreated ROS1-positive lung cancer.
abstract: Non-small-cell lung cancer is a term that encompasses a number of subtypes of lung cancer. In recent years, several intracellular pathways have been studied in order to discover a potential target for novel anticancer therapies such as anaplastic lymphoma kinase (ALK) and reactive oxygen species 1 (ROS1). Increased interest in oncologic treatment research has resulted from the observation that ALK- and ROS1-associated tyrosine kinases show molecular analogies in some of their domains. This discovery led to the hypothesis that target therapy against ALK translocation could have efficacy also in ROS1-positive tumors. Crizotinib is an oral tyrosine kinase inhibitor that binds the ALK tyrosine kinase domain, blocking its function. We report the case of a woman with heavily pretreated metastatic lung adenocarcinoma harboring ROS1 positivity who experienced a prolonged and dramatic clinical benefit from crizotinib therapy.
authors.affiliation: Department of Medical Oncology, Careggi University Hospital, Florence - Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Petreni
authors.forename: Francesca
authors.initials: F
authors.lastname: Mazzoni
authors.forename: Giulia
authors.initials: G
authors.lastname: Meoni
authors.forename: Alice
authors.initials: A
authors.lastname: Lunghi
authors.forename: Fabiana Letizia
authors.initials: FL
authors.lastname: Cecere
authors.forename: Andrea
authors.initials: A
authors.lastname: Muto
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Costanzo
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D000077547:Crizotinib; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human